Overview

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Status:
Completed
Trial end date:
2016-05-09
Target enrollment:
Participant gender:
Summary
This study is to evaluate the effects of single therapeutic and supratherapeutic oral doses of ACP-196 on the heart rate-corrected QT interval using Fridericia's formula (QTcF).
Phase:
Phase 1
Details
Lead Sponsor:
Acerta Pharma BV
Treatments:
Acalabrutinib
Moxifloxacin